Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation.
Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, Diehl L, Austin CD, Meng YG, Tan M, Bullens SL, Seeber S, Fuentes ME, Labrijn AF, Graus YM, Miller LA, Schelegle ES, Hyde DM, Wu LC, Hymowitz SG, Martin F. Seshasayee D, et al. Among authors: seeber s. J Clin Invest. 2007 Dec;117(12):3868-78. doi: 10.1172/JCI33559. J Clin Invest. 2007. PMID: 18060034 Free PMC article.
Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.
Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, Tissot AC, Tan SL, Seeber S, Schett G. Fischer JA, et al. Among authors: seeber s. Arthritis Rheumatol. 2015 Jan;67(1):51-62. doi: 10.1002/art.38896. Arthritis Rheumatol. 2015. PMID: 25303306
A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C. Thomas M, et al. Among authors: seeber s. PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6. PLoS One. 2013. PMID: 23405099 Free PMC article.
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, Varypataki EM, Richard M, Bommer E, Sam J, Joller S, Perro M, Cremasco F, Kunz L, Yanguez E, Hüsser T, Schlenker R, Mariani M, Tosevski V, Herter S, Bacac M, Waldhauer I, Colombetti S, Gueripel X, Wullschleger S, Tichet M, Hanahan D, Kissick HT, Leclair S, Freimoser-Grundschober A, Seeber S, Teichgräber V, Ahmed R, Klein C, Umaña P. Codarri Deak L, et al. Among authors: seeber s. Nature. 2022 Oct;610(7930):161-172. doi: 10.1038/s41586-022-05192-0. Epub 2022 Sep 28. Nature. 2022. PMID: 36171284 Free PMC article.
TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation.
Jin S, Chin J, Seeber S, Niewoehner J, Weiser B, Beaucamp N, Woods J, Murphy C, Fanning A, Shanahan F, Nally K, Kajekar R, Salas A, Planell N, Lozano J, Panes J, Parmar H, DeMartino J, Narula S, Thomas-Karyat DA. Jin S, et al. Among authors: seeber s. Mucosal Immunol. 2013 Sep;6(5):886-99. doi: 10.1038/mi.2012.124. Epub 2012 Dec 19. Mucosal Immunol. 2013. PMID: 23250276 Free article.
409 results